Solve Therapeutics Lands $120M to Tackle Solid Tumors With New ADC Tech

Solve Therapeutics has become one of the standout players in the booming antibody-drug conjugate (ADC) field, and its latest raise shows just how much confidence investors have in its approach. The company secured $120 million in new funding , a round led by YosemiteDealroom has a profile for this one. Try Dealroom → , the oncology-focused firm backed by Reed Jobs. The syndicate is a who’s who of life sciences investors, including AbingworthDealroom has a profile for this one. Try Dealroom →, Ally Bridge GroupDealroom has a profile for this one. Try Dealroom →, Merck & CoDealroom has a profile for this one. Try Dealroom → .Dealroom has a profile for this one. Try Dealroom → , and others who together have now brought Solve’s total funding to $321 million since its formation.

The company is built on a simple but ambitious idea: ADCs can do much better. Earlier generations of the therapy have delivered mixed results, sometimes releasing toxic payloads too early or struggling to hit the right therapeutic window. Solve believes it has a path forward. Its founders—veterans who previously built biotech startups later acquired by large pharma companies—designed a new type of “linker” intended to keep the drug intact in the bloodstream and activate only once it reaches a tumor. If it works consistently, it could expand dosing options and improve precision, two of the biggest pain points in ADC development.

With two candidates, SLV-154 and SLV-324 , now in early-stage clinical testing, Solve is entering a moment where the field is moving fast and competition is rising. Dozens of companies are experimenting with new linkers, antibodies and payloads, each trying to carve out an edge in the next wave of targeted cancer therapies. Solve’s bet is that optimizing all three components as a single integrated system—not just upgrading one piece—will deliver better performance. Early data has been “validating and consistent,” according to the company, though still too early to draw firm conclusions.

The new funding will help complete Phase 1b trials , scale operations and move the company toward more definitive tests of its technology. Solve’s lead programs target a range of solid tumors with high unmet need, including lung, head and neck, bladder and other difficult-to-treat cancers.

In a space full of big promises and rising valuations, Solve is trying to distinguish itself through engineering discipline and clinical execution. For now, its trials are enrolling ahead of schedule—an encouraging signal as attention around ADCs continues to accelerate.

Sources:
Biopharma DIVE
BusinessWire

A.M.